You are here: Home: LCU Think Tank 1 | 2006: Faculty disclosures

CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Michelle Paley, MD, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Ginelle Suarez, Chris Thomson, MD, MS, Erin Wall and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc and Genentech Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Genentech Inc/OSI Pharmaceuticals Inc, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr Choy — Professor and Chairman; Nancy B and Jake L Hamon Distinguished Chair in Therapeutic Oncology Research, Department of Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas; Consulting Fees: Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech Inc, Novartis Pharmaceuticals Corporation, Schering-Plough Corporation; Contracted Research: Eli Lilly and Company, GPC Biotech Inc. Dr Edelman — Professor of Medicine; Director of Medical Thoracic Oncology, University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland; Consulting Fees: Abraxis Oncology, Pharmacyclics, Sanofi-Aventis; Other: Abraxis Oncology, Sanofi-Aventis. Dr Herbst — Chief, Section of Thoracic Medical Oncology; Associate Professor of Medicine; Co-Director, Phase I Clinical Trials Working Group, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Consulting Fees and Contracted Research: AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Genentech Inc, Sanofi-Aventis, Taiho Pharmaceuticals Company. Dr Kim — Assistant Professor of Medicine; Director, Educational Programs, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Consulting Fees: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company/ImClone Systems, Eli Lilly and Company, Genentech Inc, Sanofi-Aventis; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Bristol-Myers Squibb Company/ImClone Systems, Eli Lilly and Company, Genentech Inc, Sanofi-Aventis; Contracted Research: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company/ImClone Systems, Eli Lilly and Company, Genentech Inc, Sanofi-Aventis. Dr Kris — Chief, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York; Consulting Fees: Boehringer Ingelheim GmbH, GlaxoSmithKline, Human Genome Sciences Inc, Merck and Company Inc, ImClone Systems. Dr Lilenbaum — Clinical Associate Professor of Medicine, University of Miami School of Medicine; Director, Thoracic Oncology Program, The Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida; Consulting Fees: Genentech Inc; Contracted Research: Sanofi-Aventis. Dr Lynch — Director, MGH Thoracic Oncology Center; Deputy Chief, Hematology Oncology; Associate Professor of Medicine, Massachusetts General Hospital, Boston, Massachusetts; Honoraria: AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Genentech Inc, OSI Pharmaceuticals, Sanofi-Aventis; Consulting Fees: Genentech Inc, Millennium Pharmaceuticals Inc, OSI Pharmaceuticals, Telik Inc; Advisor: Hana Biosciences Inc, ImClone Systems, Sanofi-Aventis. Dr Miller— Associate Attending Physician, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York; Consulting Fees: Boehringer Ingelheim GmbH, Idera Pharmaceuticals, Inc, Sanofi-Aventis; Other: Cylene Pharmaceuticals, Scientific Advisory Board. Dr Pass — Professor of Cardiothoracic Surgery and Surgery; Chief, Division of Thoracic Surgery and Thoracic Oncology, Department of Cardiothoracic Surgery, NYU School of Medicine and NCI Cancer Center, New York, New York; no financial interests or affiliations to disclose. Dr Sandler — Associate Professor of Medicine; Medical Director, Thoracic Oncology; Director, Vanderbilt-Ingram Cancer Center Affiliate Network Program, Vanderbilt University Medical Center, Division of Hematology/Oncology, Nashville, Tennessee; Consulting Fees: Genentech Inc, Sanofi-Aventis; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Genentech Inc; Contracted Research: Genentech Inc, Sanofi-Aventis. Dr Socinski — Associate Professor of Medicine, Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Abraxis Oncology, Genentech Inc, Sanofi-Aventis; Contracted Research: Abraxis Oncology, Genentech Inc, Sanofi-Aventis. Dr West — Director of Medical Therapeutics, Thoracic Oncology, Swedish Cancer Institute, Seattle, Washington; Consulting Fees: AstraZeneca Pharmaceuticals LP, Genentech Inc.

---

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Table of Contents

Top of Page